Year to date, shares of GSK have plunged 9.4% compared with the industry’s decline of 11.4%. Image Source: Zacks Investment Research Jemperli Gets CHMP Nod for Expanded Use ...

A doctor and a patient discussing a therapy plan that includes pharmaceutical products. Formerly known as GlaxoSmithKline, ...

GSK's strengths today are its HIV business, which generated >$7bn of revenues in 2024, with 4 "Blockbuster" (>$1bn revenues per annum) products, a growing oncology business which generated >$1.4bn ...

and a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for Blenrep in multiple myeloma signal significant expansion in GSK’s high-demand therapeutic portfolio.

Shingrix has become one of GSK's top-selling products, generating 3.4 billion pounds in revenue worldwide in 2023. Get access to the leaderboards pointing to tomorrow’s biggest stock movers.

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

This ongoing uncertainty adds to a challenging decade for GSK, as the company continues to struggle with the need to replenish its pharmaceutical pipeline. However, with nearly 90 products ...

GSK has extended—but with reduced volumes—an ongoing shingles vaccine partnership with local powerhouse Chongqing Zhifei Biological Products. GSK has extended its original three-year Shingrix ...